Publicacions en què col·labora amb María Dolores Caballero Barrigón (23)

2021

  1. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

    Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8

  2. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

    Leukemia, Vol. 35, Núm. 12, pp. 3585-3588

2018

  1. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment

    Hematological Oncology, Vol. 36, Núm. 5, pp. 765-772

  2. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: A long-term follow-up analysis from the Spanish GELTAMO registry

    Bone Marrow Transplantation

2017

  1. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 10, pp. 1631-1640

  2. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma

    Cancer Medicine, Vol. 6, Núm. 12, pp. 2766-2774

2016

  1. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma

    Haematologica

2011

  1. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: Toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03)

    Leukemia and Lymphoma, Vol. 52, Núm. 3, pp. 409-416

2010

  1. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: Long-term follow-up from two prospective multicenter trials

    Haematologica, Vol. 95, Núm. 7, pp. 1176-1182

2008

  1. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GEL-TAMO study group

    European Journal of Haematology, Vol. 80, Núm. 3, pp. 227-235

2006

  1. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol

    Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 2, pp. 172-183

  2. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [14]

    Leukemia

2005

  1. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)

    Clinical Cancer Research, Vol. 11, Núm. 21, pp. 7757-7763

2004

  1. Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation

    Bone Marrow Transplantation, Vol. 33, Núm. 2, pp. 183-187

2002

  1. Myeloablative treatments for multiple myeloma: Update of a comparative study of different regimens used in patients from the Spanish Registry for transplantation in multiple myeloma

    Leukemia and Lymphoma, Vol. 43, Núm. 1, pp. 67-74

2001

  1. Allogeneic transplantation of CD34+ -selected cells from peripheral blood in patients with myeloid malignancies in early phase: A case control comparison with unmodified peripheral blood tranplantation

    Bone Marrow Transplantation, Vol. 28, Núm. 4, pp. 349-354

  2. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies

    British Journal of Haematology, Vol. 114, Núm. 3, pp. 544-550

2000

  1. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

    Hematology Journal, Vol. 1, Núm. 1, pp. 28-36

  2. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: A comparative study of efficacy and toxicity from the Spanish Registry for transplantation in multiple myeloma

    British Journal of Haematology, Vol. 109, Núm. 1, pp. 138-147

1998

  1. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry

    Bone Marrow Transplantation, Vol. 21, Núm. 2, pp. 133-140